KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Arbutus Biopharma (ABUS) over the last 11 years, with Q3 2025 value amounting to $917000.0.

  • Arbutus Biopharma's Non Operating Income fell 4677.89% to $917000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 2964.4%. This contributed to the annual value of $6.4 million for FY2024, which is 2179.29% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Non Operating Income of $917000.0 as of Q3 2025, which was down 4677.89% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Non Operating Income ranged from a high of $1.8 million in Q2 2024 and a low of -$750000.0 during Q3 2021
  • In the last 5 years, Arbutus Biopharma's Non Operating Income had a median value of $1.0 million in 2025 and averaged $657736.8.
  • In the last 5 years, Arbutus Biopharma's Non Operating Income soared by 165542.17% in 2023 and then crashed by 4677.89% in 2025.
  • Arbutus Biopharma's Non Operating Income (Quarter) stood at -$525000.0 in 2021, then skyrocketed by 220.0% to $630000.0 in 2022, then soared by 127.78% to $1.4 million in 2023, then dropped by 2.37% to $1.4 million in 2024, then tumbled by 34.55% to $917000.0 in 2025.
  • Its Non Operating Income was $917000.0 in Q3 2025, compared to $1.0 million in Q2 2025 and $1.2 million in Q1 2025.